Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma?

Okuno M, Newhook TE, Joechle K, Kawaguchi Y, De Bellis M, Tzeng CD, Chun YS, Aloia TA, Shindoh J, Kaseb AO, Vauthey JN.

HPB (Oxford). 2019 Sep 16. pii: S1365-182X(19)30702-6. doi: 10.1016/j.hpb.2019.08.012. [Epub ahead of print]

PMID:
31533893
2.

Hepatocellular carcinoma response to transcatheter arterial chemoembolisation using automatically generated pre-therapeutic tumour volumes by a random forest-based segmentation protocol.

Khalaf AM, Fuentes D, Morshid A, Kaseb AO, Hassan M, Hazle JD, Elsayes KM.

Clin Radiol. 2019 Dec;74(12):974.e13-974.e20. doi: 10.1016/j.crad.2019.07.023. Epub 2019 Sep 11.

PMID:
31521326
3.

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA.

Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R.

Clin Cancer Res. 2019 Oct 15;25(20):6107-6118. doi: 10.1158/1078-0432.CCR-18-3341. Epub 2019 Jul 30.

PMID:
31363003
4.

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma.

George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM.

J Hematol Oncol. 2019 Jul 24;12(1):80. doi: 10.1186/s13045-019-0768-8.

5.

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.

Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC.

J Clin Invest. 2019 Jul 15;129(8):3324-3338. doi: 10.1172/JCI126022. eCollection 2019 Jul 15.

6.

Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.

Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P.

Cancer Immunol Res. 2019 Sep;7(9):1390-1395. doi: 10.1158/2326-6066.CIR-18-0605. Epub 2019 Jul 9.

PMID:
31289040
7.

Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study.

Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM.

J Comput Assist Tomogr. 2019 May 6. doi: 10.1097/RCT.0000000000000866. [Epub ahead of print]

PMID:
31082984
8.

Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study.

Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM.

J Comput Assist Tomogr. 2019 May/Jun;43(3):499-506. doi: 10.1097/RCT.0000000000000866.

PMID:
31082956
9.

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ.

JAMA Oncol. 2019 Jun 1;5(6):824-830. doi: 10.1001/jamaoncol.2019.0270.

PMID:
30998813
10.

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S.

Radiother Oncol. 2019 Apr;133:54-61. doi: 10.1016/j.radonc.2018.10.041. Epub 2019 Jan 16.

PMID:
30935582
11.

Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance.

Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM.

J Hepatocell Carcinoma. 2018 Jun 27;5:61-73. doi: 10.2147/JHC.S156701. eCollection 2018. Review.

12.

Editorial: charting the future of hepatocellular carcinoma publications.

Kaseb AO.

J Hepatocell Carcinoma. 2018 May 8;5:51-54. doi: 10.2147/JHC.S159650. eCollection 2018. No abstract available.

13.

Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.

Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).

Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13. Erratum in: Lancet Gastroenterol Hepatol. 2018 Jun;3(6):e3.

PMID:
29548617
14.

Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma?

Kaseb AO.

Lancet Oncol. 2017 Dec;18(12):1560-1561. doi: 10.1016/S1470-2045(17)30687-3. Epub 2017 Oct 26. No abstract available.

PMID:
29107680
15.

Anti-angiogenic therapy in the setting of TACE: an elusive synergy?

Odisio BC, Kaseb AO.

Lancet Gastroenterol Hepatol. 2018 Jan;3(1):5-6. doi: 10.1016/S2468-1253(17)30324-2. Epub 2017 Oct 4. No abstract available.

PMID:
28988686
16.

A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer.

Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E.

J Natl Compr Canc Netw. 2017 Sep;15(9):1111-1120. doi: 10.6004/jnccn.2017.0149.

PMID:
28874596
17.

Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.

Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO.

Oncology. 2017;93(4):233-242. doi: 10.1159/000455957. Epub 2017 Jul 6.

18.

Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.

Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO.

Clin Gastroenterol Hepatol. 2017 Nov;15(11):1791-1799. doi: 10.1016/j.cgh.2017.05.036. Epub 2017 Jun 1.

19.

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?

Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO.

Onco Targets Ther. 2017 Mar 3;10:1403-1412. doi: 10.2147/OTT.S111681. eCollection 2017. Review.

20.

Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma.

Kutlu OC, Chan JA, Aloia TA, Chun YS, Kaseb AO, Passot G, Yamashita S, Vauthey JN, Conrad C.

Cancer. 2017 May 15;123(10):1817-1827. doi: 10.1002/cncr.30531. Epub 2017 Jan 13.

21.

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):969-978. doi: 10.1007/s00259-016-3583-2. Epub 2016 Dec 12.

22.

Minimally invasive image-guided therapies for hepatocellular carcinoma.

Abdelsalam ME, Murthy R, Avritscher R, Mahvash A, Wallace MJ, Kaseb AO, Odisio BC.

J Hepatocell Carcinoma. 2016 Oct 11;3:55-61. eCollection 2016. Review.

23.

Type I insulin-like growth factor receptor signaling in hematological malignancies.

Vishwamitra D, George SK, Shi P, Kaseb AO, Amin HM.

Oncotarget. 2017 Jan 3;8(1):1814-1844. doi: 10.18632/oncotarget.12123. Review.

24.

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma.

Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T.

Oncotarget. 2016 Oct 25;7(43):69916-69926. doi: 10.18632/oncotarget.12066.

25.

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F.

Oncotarget. 2016 Oct 11;7(41):67521-67531. doi: 10.18632/oncotarget.11750.

26.

Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients.

Atta MM, Atta HM, Gad MA, Rashed LA, Said EM, Hassanien Sel-S, Kaseb AO.

J Hepatocell Carcinoma. 2016 Jun 14;3:19-24. doi: 10.2147/JHC.S86708. eCollection 2016.

27.

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma.

Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO.

J Hepatocell Carcinoma. 2016 Feb 5;3:1-7. doi: 10.2147/JHC.S62261. eCollection 2016.

28.

Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma.

Yamashita S, Vauthey JN, Kaseb AO, Aloia TA, Conrad C, Hassan MM, Passot G, Raghav KP, Shama MA, Chun YS.

J Gastrointest Surg. 2016 Oct;20(10):1725-31. doi: 10.1007/s11605-016-3216-x. Epub 2016 Jul 25.

PMID:
27456016
29.

Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs.

Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, Kaseb AO, Amin HM, Uthamanthil R.

Oncology. 2016;91(2):90-100. doi: 10.1159/000446074. Epub 2016 Jun 16.

30.

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.

Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC.

Onco Targets Ther. 2016 Feb 15;9:773-80. doi: 10.2147/OTT.S91977. eCollection 2016.

31.

Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.

Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH.

J Clin Oncol. 2016 Jan 20;34(3):219-26. doi: 10.1200/JCO.2015.61.3778. Epub 2015 Oct 26. Erratum in: J Clin Oncol. 2019 Apr 10;37(11):942.

32.

Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report.

Jauch SF, Morris VK, Jensen CT, Kaseb AO.

Pancreatology. 2016 Jan-Feb;16(1):153-6. doi: 10.1016/j.pan.2015.09.006. Epub 2015 Sep 28.

PMID:
26456669
33.

Reply: To PMID 25836985.

Hassan MM, Abdel-Wahab R, Li D, Kaseb AO.

Gastroenterology. 2015 Nov;149(6):1643-4. doi: 10.1053/j.gastro.2015.09.035. Epub 2015 Oct 1. No abstract available.

PMID:
26433110
34.

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.

Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R.

Oncotarget. 2015 Sep 29;6(29):28453-62. doi: 10.18632/oncotarget.4601.

35.

Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.

Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO.

Oncotarget. 2015 Aug 28;6(25):21193-207.

36.

HER2/neu-directed therapy for biliary tract cancer.

Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB.

J Hematol Oncol. 2015 May 29;8:58. doi: 10.1186/s13045-015-0155-z.

37.

The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.

Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM.

Mol Cancer. 2015 Feb 25;14:53. doi: 10.1186/s12943-015-0324-2.

38.

Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection.

Mahale P, Kaseb AO, Hassan MM, Torres HA.

Dig Liver Dis. 2015 Apr;47(4):348-9. doi: 10.1016/j.dld.2014.12.005. Epub 2014 Dec 17. No abstract available.

PMID:
25563811
39.

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma.

Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO.

J Hepatocell Carcinoma. 2015 Sep 18;2:131-42. doi: 10.2147/JHC.S81309. eCollection 2015. Review.

40.

Welcome to Journal of Hepatocellular Carcinoma.

Kaseb AO.

J Hepatocell Carcinoma. 2015 Jan 9;2:1-2. doi: 10.2147/JHC.S60647. eCollection 2015. No abstract available.

41.
42.

Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS.

J Natl Cancer Inst. 2014 May 9;106(5). pii: dju088. doi: 10.1093/jnci/dju088.

43.

TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications.

Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM.

Abdom Imaging. 2014 Oct;39(5):1070-87. doi: 10.1007/s00261-014-0130-0. Review.

PMID:
24695938
44.

Reassessing hepatocellular carcinoma staging in a changing patient population.

Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM.

Oncology. 2014;86(2):63-71. doi: 10.1159/000356573. Epub 2014 Jan 8.

45.

Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation.

Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, Shousha HI, Barakat AB, El-Desouky ED, Zayed NA, Ahmed OS, El-Din Youssef AS, Kaseb AO, Abd El-Aziz AO, Bahnassy AA.

Asian Pac J Cancer Prev. 2014 Jan;14(11):6721-6.

46.

Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma.

Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM.

Oncology. 2013;85(4):197-203. doi: 10.1159/000354698. Epub 2013 Sep 19.

47.

Beyond the basics: the differential effects of demographics and hepatitis status on treatment outcome in hepatocellular carcinoma.

Kaseb AO.

Oncology. 2013;85(1):41-3. doi: 10.1159/000352005. Epub 2013 Jul 4. No abstract available.

48.

Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.

Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN.

Cancer. 2013 Sep 15;119(18):3334-42. doi: 10.1002/cncr.28209. Epub 2013 Jul 2.

49.

Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma.

Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO.

World J Hepatol. 2013 Jun 27;5(6):332-5. doi: 10.4254/wjh.v5.i6.332.

50.

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.

Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R.

Oncotarget. 2013 Jan;4(1):156-65.

Supplemental Content

Loading ...
Support Center